Share this video  

ESMO WCGIC 2020 | Regorafenib in refractory biliary tract cancer

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, in refractory biliary tract cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).